Hoth Therapeutics Announces Expansion Of CLEER-001 Phase 2a Clinical Trial With Addition Of Regis Clinical Research As New Enrolling Site

CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment Option

NEW YORK, Feb. 24, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) today announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research as a new enrolling site. Located in Miami, Florida, Regis joins the growing CLEER-001 investigational site network as surging patient demand outpaces capacity at existing sites — a direct reflection of the compelling early clinical results HT-001 has produced and the desperate unmet need it addresses.